A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

Inclusion Criteria:

• ≥18 years old
• Received a regimen of darunavir 800 mg/ritonavir 100 mg in combination with dolutegravir 50 mg QD for ≥24 weeks as documented in EMR
• Laboratory reports (CD4, viral load, SrCr) available at time points +/- 4 6 weeks from 12, 24, 36, 48 weeks from start of regimen
• Resistance data (if applicable)

Exclusion Criteria:

• Received a regimen of darunavir/ritonavir in combination with dolutegravir for <24 weeks duration
• Patients receiving darunavir/ritonavir + DTG+NRTI's
• Missing laboratory data in ≥2 study time points
• Patients missing more than five doses over two weeks prior study visit